Patents Assigned to Tyme, Inc.
-
Patent number: 11607418Abstract: The disclosure is directed to methods of using TUDCA, or a pharmaceutically acceptable salt thereof, or a derivative thereof, for the treatment of SARS-CoV-2 infections.Type: GrantFiled: January 6, 2021Date of Patent: March 21, 2023Assignee: Tyme, Inc.Inventors: Steven Hoffman, John Rothman
-
Patent number: 11534420Abstract: Disclosed are methods for treating cancer by reduction of glycogen stores and administering tyrosine derivatives.Type: GrantFiled: May 14, 2020Date of Patent: December 27, 2022Assignee: TYME, INC.Inventor: Steven Hoffman
-
Publication number: 20220002227Abstract: The disclosure provides crystalline compositions comprising D-metyrosine and L-metyrosine, pharmaceutical formulation comprising one or more crystalline composition described herein and a pharmaceutically acceptable excipient, methods for treating cancer in a patient in need thereof, the method comprising administering to the patient one or more composition described herein, and methods for preparing the compositions described herein.Type: ApplicationFiled: July 1, 2021Publication date: January 6, 2022Applicant: Tyme, Inc.Inventor: John Zucaro
-
Publication number: 20210275467Abstract: The invention relates to tumor reducing compositions and methods thereof. Specifically, the invention relates to compositions comprising a combination of a sclerosing agent and a penetrating agent.Type: ApplicationFiled: July 2, 2019Publication date: September 9, 2021Applicant: TYME, INCInventors: Steven Hoffman, John Rothman
-
Patent number: 11103559Abstract: Pharmaceutical compositions and kits including a tyrosine hydroxylase inhibitor; melanin, a melanin promoter, or a combination thereof a p450 3A4 promoter; and a leucine aminopeptidase inhibitor are provided. Also provided are methods of treating cancer in a subject, comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof. Also provided are methods of reducing cell proliferation in a subject comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof.Type: GrantFiled: April 10, 2020Date of Patent: August 31, 2021Assignee: Tyme, Inc.Inventor: Steven Hoffman
-
Patent number: 11097234Abstract: A centrifugal mixing device can include a shaft assembly that is operably coupled to a motor such that the motor rotates the shaft assembly about a first axis. The devices can further include a turret that is rotatably coupled to the shaft assembly such that the turret rotates about the first axis relative to the shaft assembly. The turret can include a first support, a first canister rotatably coupled to the first support such that the first canister rotates about a second axis, and a second canister rotatably coupled to the first support such that the second canister rotates about a third axis. The turret is configured to rotate about the first axis in a first rotational direction and each of the first and second canisters is configured to rotate about the second and third axes, respectively, in a second rotational direction that is opposite the first rotational direction.Type: GrantFiled: June 28, 2017Date of Patent: August 24, 2021Assignee: TYME, INC.Inventor: Steven Hoffman
-
Patent number: 11058638Abstract: Provided herein are methods comprising providing a tyrosine derivative and a solid particulate material (and, optionally, melanin) and applying force to said tyrosine derivative and said solid particulate material for a time and under conditions effective to impregnate at least one of said tyrosine derivative and said solid particulate material with the other of said tyrosine derivative and said solid particulate material. The invention also provides compositions comprising at least one of a tyrosine derivative impregnated with a solid particulate material and a solid particulate material impregnated with a tyrosine derivative.Type: GrantFiled: March 6, 2017Date of Patent: July 13, 2021Assignee: Tyme, Inc.Inventor: Steven Hoffman
-
Patent number: 11052068Abstract: Pharmaceutical compositions and kits including a tyrosine hydroxylase inhibitor; melanin, a melanin promoter, or a combination thereof a p450 3A4 promoter; and a leucine aminopeptidase inhibitor are provided. Also provided are methods of treating cancer in a subject, comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof. Also provided are methods of reducing cell proliferation in a subject comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof.Type: GrantFiled: December 11, 2019Date of Patent: July 6, 2021Assignee: Tyme, Inc.Inventor: Steven Hoffman
-
Patent number: 10905698Abstract: The disclosure is directed to methods of using TUDCA, or a pharmaceutically acceptable salt thereof, or a derivative thereof, for the treatment of SARS-CoV-2 infections.Type: GrantFiled: July 6, 2020Date of Patent: February 2, 2021Assignee: Tyme, Inc.Inventors: Steven Hoffman, John Rothman
-
Publication number: 20200405680Abstract: The present disclosure is directed to transdermal compositions comprising isothiocyanates or isocyanates.Type: ApplicationFiled: September 14, 2018Publication date: December 31, 2020Applicant: Tyme, Inc.Inventor: Steven HOFFMAN
-
Patent number: 10646552Abstract: Pharmaceutical compositions and kits including a tyrosine hydroxylase inhibitor; melanin, a melanin promoter, or a combination thereof a p450 3A4 promoter; and a leucine aminopeptidase inhibitor are provided. Also provided are methods of treating cancer in a subject, comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof. Also provided are methods of reducing cell proliferation in a subject comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof.Type: GrantFiled: May 23, 2019Date of Patent: May 12, 2020Assignee: Tyme, Inc.Inventor: Steven Hoffman
-
Patent number: 10507198Abstract: Pharmaceutical compositions and kits including a tyrosine hydroxylase inhibitor; melanin, a melanin promoter, or a combination thereof; a p450 3A4 promoter; and a leucine aminopeptidase inhibitor are provided. Also provided are methods of treating cancer in a subject, comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof. Also provided are methods of reducing cell proliferation in a subject comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof.Type: GrantFiled: March 11, 2019Date of Patent: December 17, 2019Assignee: Tyme, Inc.Inventor: Steven Hoffman
-
Patent number: 10307465Abstract: Pharmaceutical compositions and kits including a tyrosine hydroxylase inhibitor; melanin, a melanin promoter, or a combination thereof; a p450 3A4 promoter; and a leucine aminopeptidase inhibitor are provided. Also provided are methods of treating cancer in a subject, comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof. Also provided are methods of reducing cell proliferation in a subject comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof.Type: GrantFiled: June 9, 2017Date of Patent: June 4, 2019Assignee: Tyme, Inc.Inventor: Steven Hoffman
-
Patent number: 10272068Abstract: Pharmaceutical compositions and kits including a tyrosine hydroxylase inhibitor; melanin, a melanin promoter, or a combination thereof a p450 3A4 promoter; and a leucine aminopeptidase inhibitor are provided. Also provided are methods of treating cancer in a subject, comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof. Also provided are methods of reducing cell proliferation in a subject comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof.Type: GrantFiled: November 15, 2016Date of Patent: April 30, 2019Assignee: Tyme, Inc.Inventor: Steven Hoffman
-
Patent number: 10010590Abstract: Pharmaceutical compositions and kits including a tyrosine hydroxylase inhibitor; melanin, a melanin promoter, or a combination thereof; a p450 3A4 promoter; and a leucine aminopeptidase inhibitor are provided. Also provided are methods of treating cancer in a subject, comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof. Also provided are methods of reducing cell proliferation in a subject comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof.Type: GrantFiled: May 19, 2016Date of Patent: July 3, 2018Assignee: Tyme, Inc.Inventor: Steven Hoffman
-
Patent number: 9895425Abstract: Pharmaceutical compositions and kits including a tyrosine hydroxylase inhibitor; melanin, a melanin promoter, or a combination thereof a p450 3A4 promoter; and a leucine aminopeptidase inhibitor are provided. Also provided are methods of treating cancer in a subject, comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof. Also provided are methods of reducing cell proliferation in a subject comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof.Type: GrantFiled: May 19, 2016Date of Patent: February 20, 2018Assignee: Tyme, Inc.Inventor: Steven Hoffman
-
Patent number: 9724657Abstract: A centrifugal mixing device can include a shaft assembly that is operably coupled to a motor such that the motor rotates the shaft assembly about a first axis. The devices can further include a turret that is rotatably coupled to the shaft assembly such that the turret rotates about the first axis relative to the shaft assembly. The turret can include a first support, a first canister rotatably coupled to the first support such that the first canister rotates about a second axis, and a second canister rotatably coupled to the first support such that the second canister rotates about a third axis. The turret is configured to rotate about the first axis in a first rotational direction and each of the first and second canisters is configured to rotate about the second and third axes, respectively, in a second rotational direction that is opposite the first rotational direction.Type: GrantFiled: October 22, 2013Date of Patent: August 8, 2017Assignee: Tyme, Inc.Inventor: Steven Hoffman
-
Patent number: 9585841Abstract: Provided herein are methods comprising providing a tyrosine derivative and a solid particulate material (and, optionally, melanin) and applying force to said tyrosine derivative and said solid particulate material for a time and under conditions effective to impregnate at least one of said tyrosine derivative and said solid particulate material with the other of said tyrosine derivative and said solid particulate material. The invention also provides compositions comprising at least one of a tyrosine derivative impregnated with a solid particulate material and a solid particulate material impregnated with a tyrosine derivative.Type: GrantFiled: October 24, 2013Date of Patent: March 7, 2017Assignee: Tyme, Inc.Inventor: Steven Hoffman
-
Patent number: 9549969Abstract: Pharmaceutical compositions and kits including a tyrosine hydroxylase inhibitor; melanin, a melanin promoter, or a combination thereof; a p450 3A4 promoter; and a leucine aminopeptidase inhibitor are provided. Also provided are methods of treating cancer in a subject, comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof. Also provided are methods of reducing cell proliferation in a subject comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof.Type: GrantFiled: June 25, 2015Date of Patent: January 24, 2017Assignee: Tyme, Inc.Inventor: Steven Hoffman